GFM
NAMS icon

GF Fund Management’s NewAmsterdam Pharma NAMS Stock Holding History

GF Fund Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.5K Sell
2,434
-112
-4% -$3.69K ﹤0.01% 351
2026
Q1 		$81.5K Buy
2,546
+318
+14% +$10.4K ﹤0.01% 359
2025
Q4 		$78.2K Sell
2,228
-195
-8% -$7.1K ﹤0.01% 365
2025
Q3 		$68.9K Buy
2,423
+58
+2% +$1.39K ﹤0.01% 364
2025
Q2 		$42.8K Hold
2,365
– – ﹤0.01% 433
2025
Q1 		$48.4K Buy
2,365
+425
+22% +$9.45K ﹤0.01% 424
2024
Q4 		$49.9K Buy
+1,940
New +$41.2K ﹤0.01% 389

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

GF Fund Management's NAMS Position: Q2 2026 in Review

GF Fund Management reduced its NewAmsterdam Pharma (NAMS) stake by 4.4% in Q2 2026, selling an estimated $3.69K and leaving 2,434 shares worth $82.5K. The position accounts for ﹤0.01% of the portfolio, ranked #351.

GF Fund Management first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • GF Fund Management held 2,434 shares of NewAmsterdam Pharma worth $82.5K as of Q2 2026.
  • GF Fund Management sold 112 NewAmsterdam Pharma shares in Q2 2026, an estimated $3.69K.
  • NewAmsterdam Pharma made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #351 holding.
  • GF Fund Management first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.